Physician profile
Mark D Turner
NPI 1902951569
$1,362.59
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $435 · 2021: $413 · 2022: $33.21 · 2023: $110 · 2024: $83.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $193.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $750.50 | 2019-2021 | |
| Amgen INC. | $361.12 | 2020-2024 | Prolia, Evenity |
| Sanofi-Aventis U.S. LLC | $51.18 | 2019-2023 | |
| Zyla Life Sciences, INC. | $26.31 | 2019 | |
| Dynasplint Systems INC. | $24.03 | 2023 | Dynasplint |
| Acell, INC. | $22.09 | 2019 | |
| Ethicon US, LLC | $20.42 | 2022 | |
| Solventum Corporation | $19.45 | 2024 | Activ.A.C. |
| Bioventus LLC | $17.21 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.53 | 2023 | Seglentis |
| Orthogenrx INC. | $15.88 | 2019 | |
| Depuy Synthes Sales INC. | $13.08 | 2020 | |
| Horizon Therapeutics Plc | $12.79 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.